AbbVie (ABBV) ended the recent trading session at $201.64, demonstrating a -1.73% swing from the preceding day's closing price. This change was narrower than the S&P 500's daily loss of 4.84%. On ...

AbbVie has been actively advancing its oncology portfolio with recent presentations at the AACR Annual Meeting, showcasing developments like ABBV-969 and ABBV-514, both highlighting innovation in ...

AbbVie (ABBV) closed the most recent trading day at $213.85, moving -0.29% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.07%. At the same ...

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of ...

My last analysis on AbbVie Inc. (NYSE:ABBV) stock was published more than a month ago. More specifically, that article, titled “AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer ...

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other best pharma stocks to buy according to hedge funds. The US pharmaceutical sector is ...

Try it free for 7 days AbbVie Inc ABBV released on Saturday the final analysis of the confirmatory Phase 3 MIRASOL trial of Elahere (mirvetuximab soravtansine-gynx) in women with folate receptor ...